A significant trial of the daily weight-loss pill orforglipron has shown promising results, helping participants shed an average of 7.3kg (16lbs) over nine months while also reducing blood sugar levels in those with type 2 diabetes. Conducted by Eli Lilly, this phase 3 clinical trial positions orforglipron as a potential new treatment option in the ongoing fight against obesity and diabetes. The findings underscore the pill’s effectiveness, contributing to its candidacy among new medications aimed at addressing these health issues.
